CN108368053A - 作为抗菌化合物的取代的苯并氮杂环己烯酮 - Google Patents

作为抗菌化合物的取代的苯并氮杂环己烯酮 Download PDF

Info

Publication number
CN108368053A
CN108368053A CN201680072228.9A CN201680072228A CN108368053A CN 108368053 A CN108368053 A CN 108368053A CN 201680072228 A CN201680072228 A CN 201680072228A CN 108368053 A CN108368053 A CN 108368053A
Authority
CN
China
Prior art keywords
chain
linear chain
branched chain
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680072228.9A
Other languages
English (en)
Chinese (zh)
Inventor
金琦
D.T.波尔豪斯
J.斯普莱特斯托泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN108368053A publication Critical patent/CN108368053A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680072228.9A 2015-12-08 2016-12-08 作为抗菌化合物的取代的苯并氮杂环己烯酮 Pending CN108368053A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264628P 2015-12-08 2015-12-08
US62/264,628 2015-12-08
PCT/IB2016/057451 WO2017098440A1 (en) 2015-12-08 2016-12-08 Substituted benzazinones as antibacterial compounds

Publications (1)

Publication Number Publication Date
CN108368053A true CN108368053A (zh) 2018-08-03

Family

ID=57680436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680072228.9A Pending CN108368053A (zh) 2015-12-08 2016-12-08 作为抗菌化合物的取代的苯并氮杂环己烯酮

Country Status (10)

Country Link
US (2) US10781184B2 (enExample)
EP (1) EP3386950A1 (enExample)
JP (1) JP2019501896A (enExample)
KR (1) KR20180088456A (enExample)
CN (1) CN108368053A (enExample)
AU (2) AU2016367510A1 (enExample)
BR (1) BR112018011670A2 (enExample)
CA (1) CA3007653A1 (enExample)
RU (1) RU2018124788A (enExample)
WO (1) WO2017098440A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109593066A (zh) * 2018-12-21 2019-04-09 上海交通大学 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
MX379690B (es) * 2016-09-28 2025-03-11 Dong A St Co Ltd Derivados de tetrahidropiridina y su uso como agentes antibacterianos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777577A (zh) * 2003-01-08 2006-05-24 希龙公司 抗菌剂
WO2015164458A1 (en) * 2014-04-22 2015-10-29 Novartis Ag Isoxazoline hydroxamic acid derivatives as lpxc inhibitors
WO2015173329A1 (en) * 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765585B (zh) * 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
SI2512474T1 (sl) * 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777577A (zh) * 2003-01-08 2006-05-24 希龙公司 抗菌剂
WO2015164458A1 (en) * 2014-04-22 2015-10-29 Novartis Ag Isoxazoline hydroxamic acid derivatives as lpxc inhibitors
WO2015173329A1 (en) * 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NING GAO ET AL.: "Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain", 《PROTEIN EXPRESSION AND PURIFICATION》 *
方敏，等.: "抗革兰阴性菌新靶点：脱乙酰基酶(LpxC)及其抑制剂研究进展", 《世界临床药物》 *
赵桂森,等: "《新药设计与开发基础》", 30 November 2015, 济南：山东大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109593066A (zh) * 2018-12-21 2019-04-09 上海交通大学 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用
CN109593066B (zh) * 2018-12-21 2020-06-19 上海交通大学 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用

Also Published As

Publication number Publication date
AU2019271952A1 (en) 2019-12-19
EP3386950A1 (en) 2018-10-17
JP2019501896A (ja) 2019-01-24
RU2018124788A (ru) 2020-01-15
AU2016367510A1 (en) 2018-06-07
KR20180088456A (ko) 2018-08-03
US10781184B2 (en) 2020-09-22
WO2017098440A1 (en) 2017-06-15
CA3007653A1 (en) 2017-06-15
US20180362474A1 (en) 2018-12-20
RU2018124788A3 (enExample) 2020-03-18
BR112018011670A2 (pt) 2018-11-27
US20210053926A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JP6530773B2 (ja) ２，３−二置換１−アシル−４−アミノ−１，２，３，４−テトラヒドロキノリン誘導体及びブロモドメイン阻害薬としてのそれらの使用
CN114728912A (zh) Mta-协同prmt5抑制剂
CN104902895B (zh) 可用作用于治疗增生性疾病的激酶抑制剂的二氢萘啶和相关化合物
CN109195965B (zh) Wdr5蛋白质-蛋白质结合的抑制剂
TWI736517B (zh) 作為抗癌劑之新穎三環化合物
CN105829305B (zh) Nrf2调节剂
CN105693720B (zh) 作为trk激酶抑制剂的大环化合物
TWI605041B (zh) 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應之調節劑之經醯胺基取代雜環化合物
CN106170489B (zh) 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
JP2020518601A (ja) ヒト免疫不全ウイルス複製の阻害剤
CN110511209A (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
CN108368053A (zh) 作为抗菌化合物的取代的苯并氮杂环己烯酮
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
TW201524958A (zh) 用作轉染期間重排抑制劑之新穎化合物
CN111601807B (zh) Menin-mll相互作用的外型-氮杂螺抑制剂
CN110049983A (zh) 药物化合物
CN110869373B (zh) 抗生素抗性破坏剂
CN116390919A (zh) 一种芳香化合物、其制备方法及应用
CN111566103A (zh) 作为激酶抑制剂的氨基咪唑并吡嗪
CN114127063B (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN114650992A (zh) Gpr52调节剂化合物
CN114450274A (zh) 作为lrrk2抑制剂的吲唑及氮杂吲唑
WO2023202642A1 (zh) Rho相关蛋白激酶抑制剂及其制备和应用
WO2024051784A1 (zh) 一种含氮杂环化合物、其药物组合物及应用
CN112513041B (zh) 三环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180803

WD01 Invention patent application deemed withdrawn after publication